Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

Biotechnology

Healthcare
$2.11 +1.84%

+$0.06 today

Market cap
$235.60M
Beta
0.47
P/E (TTM)
-1.7
EPS (TTM)
-$1.87
52W Low $2.40High $5.45

Volume 1.79M

Average 3.15M

Returns on capital

Rocket Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-80.5%

avg -49.6%

ROIC

-75.4%

avg -37.8%

ROA

-67.5%

avg -39.4%

Analysis

ROA is currently the strongest return metric at -67.5% versus its period average of -39.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Gaurav D. Shah

Chief Executive Officer & DirectorUSD 1.09M51——

Martin Louis Wilson

Gen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corporation OfficerUSD 767.47K50——

Jonathan Schwartz

Chief Science & Gene Therapy OfficerUSD 614.33K62——

Christopher Stevens

Chief Operating OfficerUSD 604.47K46——

Kevin Giordano

Director of Corporate Communications————

Joseph Manhede

Principal Accounting Officer—4852.58K0.05%

Sarbani Chaudhuri

Chief Commercial Officer—51257.94K0.24%

Syed Ali-Aamir Rizvi

Chief Medical Officer—5993.04K0.09%

Meg Dodge

Senior Vice President & Head of External Affairs————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 9, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$34,400.00

Sells

27

$1.00M

Net Transaction Value

−$968,754.84

Net selling

Most Active

Wilson Martin

9 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 9, 26

Chaudhuri Sarbani

Direct

Sell$11.3K
Nov 5, 26

Wilson Martin

Direct

Sell$127.8K
Sep 11, 26

Wilson Martin

Direct

Sell$256.5K
Aug 18, 26

Wilson Martin

Direct

Sell$2.1K
Aug 18, 26

Shah Gaurav

Direct

Sell$7.8K
Aug 13, 26

Shah Gaurav

Direct

Sell$9.6K
Aug 13, 26

Wilson Martin

Direct

Sell$11.8K
Aug 11, 26

Stevens Christopher James

Direct

Sell$128.3K
Aug 11, 26

Chaudhuri Sarbani

Direct

Sell$16.4K
May 21, 26

Shah Gaurav

Direct

Sell$171.8K

1–10 of 28

Summary

Insiders reported 1 buys worth $34,400.00 and 27 sells worth $1.00M over the last 12 months. That adds up to net selling of $968,754.84. Wilson Martin was the most active insider with 9 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/AN/A
N/A7 analysts
Net IncomeN/AN/AN/A
N/A7 analysts
EBITN/AN/AN/A
N/A7 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Rocket Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about RCKT's management, answered from reported figures.

Who manages RCKT?

Rocket Pharmaceuticals, Inc. (RCKT) lists 9 active executives. The top listed executive is Kevin Giordano, Director of Corporate Communications.

Are RCKT insiders buying or selling?

Recent insider activity shows net buying of $59.37M.